Imagion Biosystems : April 2022 Investor Newsletter

®

IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

U.S. Media Contact:	Australian Media & Investor Relations:
Casie Ost	Hannah Howlett, WE Communications
[e-mail]	[e-mail]
[phone]	[phone]
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com

14 April 2022

Imagion Biosystems April 2022 Investor Newsletter

MELBOURNE - Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide its investors with its April 2022 Investor Newsletter.

The newsletter details recent new company developments and activities, including:

•  Message from the CFO, Mr Geoff Hollis;

•  Recap of MagSense® HER2 Breast Cancer Study Update;

•  Employee spotlight, Mr Dan Inglese, Research Associate;

•  Welcome to TJ Stalvey, Senior Director, Clinical Operations; and

•  Imagion Biosystems in the news, Edison Group open house.

The investor newsletter can be viewed below or at this link:https://imagionbiosystems.hubspotpagebuilder.com/april-2022-investor-newsletter.

Imagion Biosystems normally distributes this update as an e-newsletter. Investors can sign up to receive email updates at this link:https://info.imagionbio.com/investor-newsletter-sign-up

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visitwww.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

View in browser

Investor Newsletter: Issue 16 | April 2022

A Message From the CFO

Dear Shareholders,

I am happy to share with you our latest investor newsletter with updates on Imagion's recent activities.

I have recently returned from two weeks in San Diego, the first time I was able to visit the team since I joined Imagion in December 2020. I must say I was very impressed; the new facility is fantastic and will set us up well for the future. What was more impressive was the team behind Imagion. Being able to immerse myself with them for two weeks has been invaluable and I return home to Australia knowing we are in very good hands. I hope you enjoy getting to know the wider Imagion team via the newsletter profiles.

As a CFO, you are often tasked with solely focusing on the numbers - profits and numbers trending in the right direction are and will always be important - but when I joined Imagion, I was hoping there was a more altruistic purpose to the role. After spending some time in San Diego, I now fully understand there is a shared sense of purpose to improve cancer detection to help save lives. Working for a business that is dedicated to improving people's lives is something I can be proud of, and I look forward to continuing to support my team to achieve those goals.

We were pleased to provide you with a study update in relation to our MagSense® HER2 breast cancer Phase I study in March. I would like to reiterate Bob's sentiments in that it is indeed exciting to begin accumulating patient data and see the positive direction of the preliminary results. I do want to stress that the data is only preliminary, hence why full scientific results have not been released. This will come at a suitable time as the study progresses.

Although the Phase I study is a key part of our path forward for 2022, there are many other developments currently underway - including our work on prostate cancer and brain cancer. We anticipate sharing updates on these developments with you as they materialise throughout the year.

If anyone has any investor-related queries, please note that I can be reached [e-mail]. I genuinely enjoy engaging with our shareholders and will always try to be prompt with my replies, please keep in mind there is only one of me though!

Thanks again to all our shareholders for your continued support and I look forward to sharing the year ahead with you all.

MagSense® HER2 Breast Cancer Study Update

We were pleased to release an update on the progress of the MagSense® HER2 breast cancer study last month. To recap the announcement, the top highlights include:

Interim data support MagSense® imaging agent is safe and well-toleratedResults make evident that the imaging agent is reaching the patient's lymph nodes

Executive Chairman and CEO, Bob Proulx, indicates "we are encouraged by these preliminary observations from our investigators."

Read the Full Announcement

Get to Know Our Imagioneers!

Today we're highlighting Dan Inglese. He is one of our research associates and is an integral member of our team, undertaking important preclinical research as we develop our pipeline as well as being involved in the assessment of the clinical samples from our Phase I study. By the way, if you're ever in San Diego, he's an excellent tour guide! Be sure to check out our interview with Dan to learn more about his background and interests.

Read More About Dan

OTHER RECENT NEWS...

Investor Deck and Annual Reports are Available

Our Full Year Financial Results, 2021 Annual Report, and an updated Investor Presentation are now available. We start 2022 with our clinical study well underway and momentum in our research programs.

Read the Updates ⇒

Annual General Meeting & Other Company Updates

Our next Annual General Meeting will be hybrid, both virtually and in-person, held in Melbourne on 25th May 2022. A notice of the meeting will be released on 22nd April with further details. Our CEO, Bob Proulx, will be in attendance along with the majority of our Directors. It will be a good chance for shareholders to hear from theteam in person. Also, our Appendix 4C and Quarterly Update will be released later in April.

Read Our Latest News ⇒

Welcome TJ Stalvey!

Now as a clinical-stage company, it is important that we add people to our team with the kind of expertise to help us expand our development capacities to bring us to the next stage. TJ Stalvey recently joined us to help drive our global clinical operations.

"What drew me to Imagion is the vision and challenge of pairing our unique asset with the opportunity to improve the lives of people facing cancer." - TJ

Learn More About TJ

⇒

Imagion Biosystems in the News:

In case you missed theEdison Group open house, we discussed in detail, the nanotechnology behind our bio-imaging MagSense technology and where we hope to make a big difference in early cancer detection.